Stock Scorecard
Stock Summary for Protagonist Therapeutics Inc (PTGX) - $44.27 as of 5/13/2025 9:00:28 PM EST
Total Score
16 out of 30
Safety Score
49 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for PTGX
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PTGX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PTGX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PTGX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for PTGX (49 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 2 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for PTGX
Financial Details for PTGX
Company Overview |
|
|---|---|
| Ticker | PTGX |
| Company Name | Protagonist Therapeutics Inc |
| Country | USA |
| Description | Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 44.27 |
| Price 4 Years Ago | 34.20 |
| Last Day Price Updated | 5/13/2025 9:00:28 PM EST |
| Last Day Volume | 908,794 |
| Average Daily Volume | 1,167,701 |
| 52-Week High | 60.60 |
| 52-Week Low | 27.00 |
| Last Price to 52 Week Low | 63.96% |
Valuation Measures |
|
| Trailing PE | 58.04 |
| Industry PE | 29.04 |
| Sector PE | 49.22 |
| 5-Year Average PE | -55.52 |
| Free Cash Flow Ratio | 19.68 |
| Industry Free Cash Flow Ratio | 19.04 |
| Sector Free Cash Flow Ratio | 31.82 |
| Current Ratio Most Recent Quarter | 17.26 |
| Total Cash Per Share | 2.25 |
| Book Value Per Share Most Recent Quarter | 11.13 |
| Price to Book Ratio | 4.07 |
| Industry Price to Book Ratio | 38.21 |
| Sector Price to Book Ratio | 30.58 |
| Price to Sales Ratio Twelve Trailing Months | 13.50 |
| Industry Price to Sales Ratio Twelve Trailing Months | 93.50 |
| Sector Price to Sales Ratio Twelve Trailing Months | 25.54 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 4 |
Share Statistics |
|
| Total Shares Outstanding | 61,957,000 |
| Market Capitalization | 2,742,836,390 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 351.30% |
| Annual Earnings Growth | 448.54% |
| Reported EPS 12 Trailing Months | 0.78 |
| Reported EPS Past Year | -0.19 |
| Reported EPS Prior Year | 4.20 |
| Net Income Twelve Trailing Months | 56,193,000 |
| Net Income Past Year | 275,188,000 |
| Net Income Prior Year | -78,955,000 |
| Quarterly Revenue Growth YOY | -88.90% |
| 5-Year Revenue Growth | 351.71% |
| Operating Margin Twelve Trailing Months | -68.20% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 139,653,000 |
| Total Cash Past Year | 97,249,000 |
| Total Cash Prior Year | 186,727,000 |
| Net Cash Position Most Recent Quarter | 139,653,000 |
| Net Cash Position Past Year | 97,249,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 9,794,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 675,295,000 |
| Total Stockholder Equity Prior Year | 336,677,000 |
| Total Stockholder Equity Most Recent Quarter | 689,052,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 335,286,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 5.41 |
| Free Cash Flow Past Year | 182,797,000 |
| Free Cash Flow Prior Year | -70,845,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.72 |
| MACD Signal | -0.48 |
| 20-Day Bollinger Lower Band | 31.75 |
| 20-Day Bollinger Middle Band | 42.16 |
| 20-Day Bollinger Upper Band | 52.57 |
| Beta | 2.64 |
| RSI | 41.25 |
| 50-Day SMA | 41.30 |
| 150-Day SMA | 25.95 |
| 200-Day SMA | 26.69 |
System |
|
| Modified | 5/13/2025 8:56:24 AM EST |